Skip to main
GRI

GRI Stock Forecast & Price Target

GRI Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GRI Bio is a clinical-stage biotech company with a focus on discovering and developing therapies for dysregulated immune responses. The company's two product candidates, GRI-0621 and GRI-0803, have shown promising results in treating serious diseases associated with inflammatory, fibrotic, and autoimmune disorders. With a large market potential for its treatment of idiopathic pulmonary fibrosis, positive top-line data, and a prime location in La Jolla, CA, GRI Bio presents a positive outlook for its long development and commercialization roads, despite the inherent risks of clinical trials and commercial failures.

Bears say

GRI Bio is a clinical stage biotech company with a negative EPS of $(13.30) and no Q4 guidance. Its main focus is the development of GRI-0621 for the treatment of IPF, with other product GRI-0803 targeting potential autoimmune disorders. The company's recent financial results and history of preclinical work in SLE and MS indicate potential risks and uncertainties, leading to the negative outlook and a revised 12-month price target of $36 (based on NPV analysis).

GRI has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRI Bio Inc (GRI) Forecast

Analysts have given GRI a Strong Buy based on their latest research and market trends.

According to 2 analysts, GRI has a Strong Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRI Bio Inc (GRI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.